Tempus AI (TEM +3.81%) is trying to build more than a diagnostics business. Its growing healthcare data platform, artificial intelligence tools, FDA progress, and pharma partnerships could create meaningful upside if the company can scale profitably. But the stock already reflects high expectations, making execution the key issue for investors.
*Stock prices used were the market prices of June 1, 2026. The video was published on June 7, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.